New venture funds and leading startups are shaping the future of biotechnology. T.Rx Capital, co-founded by biotech veteran Robert Langer's son, announced a $77.5 million inaugural fund to invest in visionary founders at the intersection of biology and technology. The 2025 Endpoints 11 list recognized promising private biotech companies including Chai Discovery for AI-driven drug design, Umoja Biopharma aiming to overcome CAR-T barriers, and Candid Therapeutics developing novel autoimmune treatments, signaling accelerating innovation across the sector.